Panchrotal wrote:
承辦人的姓名寫在上面
你可以自己去求證
查不到我可以給你承辦人電話
Deoxyribose wrote:
沒電話號碼是要怎麼打啦
直接講哪一間警察局不就得了?
還有, 你是不知道我就算打去警察也不會隨便告訴我嗎?
還一直叫人打電話?
你查不到要說啊
整天只會傻笑
個人積分：5083分
文章編號：82045716
個人積分：24049分
文章編號：82045770
個人積分：6101分
文章編號：82046585
個人積分：1024分
文章編號：82047013
惡魔的右手 wrote:
不是吧? WHO也認證了中國的國藥以及科興
但有極大的機率是政治因素不得不認證的
畢竟有太多國家打了中國疫苗,感染人數還是直線上升...
有效程度最樂觀的估計也才50幾%
日本是因為自己買的量超過全國人民所需(總採購量超過3億劑)\
而且AZ疫苗即將在日本國內自行生產(預計會超過5000萬劑),
所以才有多的疫苗送給台灣
對對對AZ超有效的
可是你口中超有效的AZ疫苗在英國的成績並不算很好
英國主要打的是AZ疫苗，目前英國已施打第一劑的疫苗約佔57.8%以上，接種兩劑的佔36%
但是英國目前已有科學家警告英國會再有一波疫情爆發，以英國的疫苗注射率都快接近群體免疫了
這樣都還會有可能再發生一波新疫情，要知道現在英國可還沒解封
而 WHO也認證了中國的國藥以及科興，這確是因為已經政治因素，因為已經因政治因素拖延太久了不能再拖，要不然再拖下去WHO的信譽就要受損了
全世界第一批次其他疫苗大多是去年年底、今年年初通過的，而同樣差不多時間做延三期試驗的中國的國藥以及科興拖到很後面才獲得WHO的緊急授權
是中國的國藥、科興疫苗很差嗎，中國的國藥、科興的三期試驗直接就是在當地國家做的，而且是跟當地的醫療、研究單位合作一起做的，有沒有效當地國家會不知道嗎
所以這些國家及周邊國家都是不甩WHO的緊急授權就開始進口施打，甚至於英國都有俱樂部推出有錢人到杜拜、阿拉伯聯合大公國打中國的國藥疫苗的服務，國藥疫苗不好英國有錢人會去打
所以當中國的國藥、科興一直賣到全世界其他國家，而WHO還卡著緊急授權不發反而會損害WHO的信譽
個人積分：963分
文章編號：82048838
個人積分：3610分
文章編號：82049060
個人積分：14分
文章編號：82049138
牛杯杯0216 wrote:
任何疫苗都有風險，如果有得選我選輝瑞，但是輝瑞真的比較好嗎?我不知道，但是被媒體爆成這樣，小老百姓心中會怕也是事實，不過沒得選我連國產也只能硬著頭皮打，媒體說的每天不一樣，我這門外漢能怎麼辦?這十幾年來的流感疫苗有沒有問題?有!但是媒體沒有出來大力亂說，所以怕的人就明顯的少，而我從來就沒打過流感疫苗，不是怕只是不想打，因為自認得流感感覺沒那麼可怕!
無論是什麼疫苗，都沒走完人體試驗的全程測試，安全性本來就有疑慮，只是疫情當前只能緊急通過開兩權相害兩權相害取其輕!
如果你是亞洲人的話，被你猜對了(媒體 vs. 事實不一樣)，你還蠻聰明的，呵呵
美國已經有初步結果了，Pfizer對亞洲人比較無效 (只有74%的效力)
目前應該是Moderna對亞洲人比Pfizer有效
如果有黑人血統，選擇輝瑞應該是不錯
如果是雜種的話，應該是Moderna比較好，(Pfizer對雜種只有10.4%的效力)
https://www.spectrumhealth.org/-/media/spectrumhealth/documents/covid/for-providers/pfizer-and-moderna-sars-cov-2-vaccines-faq.pdf?rev=197c1f54b497400bbc02c789a1d1a83e
How effective is this vaccine?
Note that the question of effectiveness can only be answered through studies after the vaccine is
distributed.
Efficacy rates are determined through clinical trials. In the clinical trials conducted to support emergency use
authorization (EUA), over 36,000 individuals received both injections of the vaccine. There were nine
COVID-19 cases among participants who received both injections of the Pfizer vaccine and 11 cases
among those who received the Moderna vaccine. The Pfizer placebo group reported 169 cases. Moderna’s
placebo group reported 185.
The Pfizer vaccine demonstrated >90% efficacy across all age, gender and race groups, including obese
participants and those with medical co-morbidities. The exception was for Asians, where efficacy was 75%.
Researchers don’t know why the vaccine appears less efficacious in this group and it will require further
study before any definitive conclusions can be made. The vaccine efficacy was 82% after only one dose;
however, the vast majority of participants received two doses; so, it is difficult to draw firm conclusions about
the efficacy of only one dose.
The Moderna vaccine demonstrated >90% efficacy except in persons >65; for that group, the vaccine,
where the efficacy was 86%. Overall, the Moderna vaccine demonstrated >90% efficacy for participants
receiving one or two doses, but like the Pfizer vaccine, the vast majority of participants received both doses
and thus no firm conclusions can be drawn about the efficacy of only one dose.
How the COVID-19 vaccines from Moderna and Pfizer compare head to head
All five of the people in the Moderna trial who developed COVID-19 after receiving the vaccine were white. As a result, the Moderna vaccine was 100% effective in Black, Latino and Asian Americans, as well as in people with mixed racial backgrounds. Vaccine efficacy could not be determined for Native Americans or Pacific Islanders because there were no cases of COVID-19 in either the vaccine or the placebo groups.
In its Phase 3 trial, the Pfizer vaccine was 100% effective for Black study participants and 94.5% effective for Latino participants, slightly below the 94.7% effectiveness for white subjects. In addition, it was 74.4% effective in Asian Americans, and 100% effective in Native Americans and Pacific Islanders. Among people described as multiracial, it was only 10.4% effective, with one case of COVID-19 among those who got the vaccine and one case among those who got the placebo.
個人積分：5083分
文章編號：82049966
個人積分：7126分
文章編號：82050168
個人積分：6101分
文章編號：82052778
